Some of the German group's shareholders have voiced concern that Bayer risks neglecting its drugs business following its planed $63.5 billion takeover of U.S. seeds group Monsanto , which won U.S. approval on Tuesday.
Reuters, St. Louis Post-Dispatch: Business
Thu, 05/31/2018 - 4:00am
Some of the German group's shareholders have voiced concern that Bayer risks neglecting its drugs business following its planed $63.5 billion takeover of U.S. seeds group Monsanto , which won U.S. approval on Tuesday.